Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL

(MedPage Today) -- Initial treatment with lenalidomide (Revlimid), tafasitamab (Monjuvi), rituximab, and acalabrutinib (Calquence) led to complete responses (CRs) in 64% of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), according...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news